Evidence map›Paper›PMID 29073049›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2017

Production of diverse PET probes with limited resources: 24

Jeffrey Collins, Christopher M Waldmann, Christopher Drake, Roger Slavik, Noel S Ha, Maxim Sergeev, Mark Lazari, Bin Shen, Frederick T Chin, Melissa Moore and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Review
  3. Optimization and comparison of [American journal of nuclear medicine and molecular imaging · 2025
    Article
  4. Development ofChemical communications (Cambridge, England) · 2023
    Article
  5. Article
  6. Detrimental impact of aqueous mobile phases on 18F-labelled radiopharmaceutical analysisAnalytical methods : advancing methods and applications · 2023
    Article
  7. Effective Preparation of [Molecules (Basel, Switzerland) · 2022
    Article
  8. Article
  9. STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  10. Optimization of Radiochemical Reactions using Droplet Arrays.Journal of visualized experiments : JoVE · 2021
    Article
  11. Article
  12. Nucleophilic Synthesis of 6-l-[Molecules (Basel, Switzerland) · 2020
    Review
  13. Green and efficient synthesis of the radiopharmaceutical [Reaction chemistry & engineering · 2020
    Article
  14. Article
  15. A Dual-Modality Linker Enables Site-Specific Conjugation of Antibody Fragments forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Article
  16. Article
  17. Article
  18. European journal of nuclear medicine and molecular imaging · 2019
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Jeffrey CollinsDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
Christopher M WaldmannDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
Christopher DrakeSofie Biosciences, Inc., Culver City, CA 90230.
Roger SlavikAhmanson Translational Imaging Division, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
Noel S HaDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
Maxim SergeevDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
Mark LazariDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
Bin ShenDepartment of Radiology, Stanford University, Stanford, CA 94305.
Frederick T ChinDepartment of Radiology, Stanford University, Stanford, CA 94305.
Melissa MooreSofie Biosciences, Inc., Culver City, CA 90230.
Saman SadeghiDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
Michael E PhelpsDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095; mphelps@mednet.ucla.edu mvandam@mednet.ucla.edu.
Jennifer M MurphyDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
R Michael van DamDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095; mphelps@mednet.ucla.edu mvandam@mednet.ucla.edu.ORCID 0000-0003-2316-0173
University of California, Los Angeles · USSofie Biosciences (United States) · USStanford University · US

Funding

UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REITER, ROBERT E · 2002 to 2023
$42.6M
UCLA Institute for Molecular Medicine (IMED) CoreU54CA151819 · NCI · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI RADU, CAIUS GABRIEL · 2010 to 2014
$12.1M
Automated microfluidic production of high specific activity PET tracers to enable routine CNS imagingR21AG049918 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VAN DAM, ROBERT MICHAEL · 2015 to 2017
$693k
Compact microfluidic PET probe concentrator for preclinical and in vitro imagingR21CA174611 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VAN DAM, ROBERT MICHAEL · 2013 to 2015
$663k
Electrochemical Synthesis of RadiopharmaceuticalsR21CA186842 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SADEGHI, SAMAN · 2016 to 2018
$616k
Microliter radiosynthesizer for producing high specific activity PET ligandsR21EB015540 · NIBIB · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VAN DAM, ROBERT MICHAEL · 2012 to 2013
$405k
NCI NIH HHS HHSN261201400041CNCI NIH HHS P50 CA092131NCI NIH HHS R21 CA174611NCI NIH HHS R21 CA186842NCI NIH HHS U54 CA151819NIA NIH HHS R21 AG049918NIBIB NIH HHS R21 EB015540
6 · The paper itself

Abstract

New radiolabeled probes for positron-emission tomography (PET) are providing an ever-increasing ability to answer diverse research and clinical questions and to facilitate the discovery, development, and clinical use of drugs in patient care. Despite the high equipment and facility costs to produce PET probes, many radiopharmacies and radiochemistry laboratories use a dedicated radiosynthesizer to produce each probe, even if the equipment is idle much of the time, to avoid the challenges of reconfiguring the system fluidics to switch from one probe to another. To meet growing demand, more cost-efficient approaches are being developed, such as radiosynthesizers based on disposable "cassettes," that do not require reconfiguration to switch among probes. However, most cassette-based systems make sacrifices in synthesis complexity or tolerated reaction conditions, and some do not support custom programming, thereby limiting their generality. In contrast, the design of the ELIXYS FLEX/CHEM cassette-based synthesizer supports higher temperatures and pressures than other systems while also facilitating flexible synthesis development. In this paper, the syntheses of 24 known PET probes are adapted to this system to explore the possibility of using a single radiosynthesizer and hot cell for production of a diverse array of compounds with wide-ranging synthesis requirements, alongside synthesis development efforts. Most probes were produced with yields and synthesis times comparable to literature reports, and because hardware modification was unnecessary, it was convenient to frequently switch among probes based on demand. Although our facility supplies probes for preclinical imaging, the same workflow would be applicable in a clinical setting.

Indexed as

Fluorine RadioisotopesPositron-Emission TomographyRadiochemistryRadiopharmaceuticalsFluorine RadioisotopesRadiopharmaceuticalsPET tracerpositron-emission tomographyradiochemistryradiosynthesis moduleresource efficiency

Identifiers

PMID29073049
PMCPMC5664529
OpenAlexW2762880763

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.